PMID- 36530751
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 13
DP  - 2022
TI  - Monocyte or white blood cell counts and beta(2) microglobulin predict the durable 
      efficacy of daratumumab with lenalidomide.
PG  - 20406207221142487
LID - 10.1177/20406207221142487 [doi]
LID - 20406207221142487
AB  - BACKGROUND: Daratumumab is one of the most widely used treatments for 
      relapsed/refractory multiple myeloma (MM) patients. However, not all patients 
      achieve a lasting therapeutic response with daratumumab. OBJECTIVES: We 
      hypothesized that a durable response to daratumumab could be predicted by the 
      balance between the MM tumor burden and host immune status. DESIGN: We conducted 
      a retrospective study using the real-world data in the Kansai Myeloma Forum (KMF) 
      database. METHODS: We retrospectively analyzed 324 relapsed/refractory MM 
      patients who were treated with daratumumab in the KMF database. RESULTS: In this 
      study, 196 patients were treated with daratumumab, lenalidomide, and 
      dexamethasone (DLd) regimen and 128 patients were treated with daratumumab, 
      bortezomib, and dexamethasone (DBd) regimen. The median age at treatment, number 
      of prior treatment regimens and time-to-next-treatment (TTNT) were 68, 4 and 8.02 
      months, respectively. A multivariate analysis showed that the TTNT under the DLd 
      regimen was longer with either higher monocyte counts (analysis 1), higher white 
      blood cell (WBC) counts (analysis 2), lower beta(2) microglobulin (B2MG < 5.5 mg/L) 
      or fewer prior regimens (<4). No parameters were correlated with TTNT under the 
      DBd regimen. CONCLUSION: We propose a simple scoring model to predict a durable 
      effect of the DLd regimen by classifying patients into three categories based on 
      either monocyte counts (0 points for ⩾200/mul; 1 point for <200/mul) or WBC counts 
      (0 points for ⩾3500/mul; 1 point for <3500/mul) plus B2MG (0 points for <5.5 mg/L; 
      1 point for ⩾5.5 mg/L). Patients with a score of 0 showed significantly longer 
      TTNT and significantly better survival compared to those with a score of 1 or 2 
      (both p < 0.001). To confirm this concept, our results will need to be validated 
      in other cohorts.
CI  - (c) The Author(s), 2022.
FAU - Shimazu, Yutaka
AU  - Shimazu Y
AUID- ORCID: 0000-0002-1604-7220
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Kanda, Junya
AU  - Kanda J
AUID- ORCID: 0000-0002-6704-3633
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Kawaramachi, Shogoin, Sakyoku, Kyoto 606-8507, Japan.
FAU - Kaneko, Hitomi
AU  - Kaneko H
AD  - Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
FAU - Imada, Kazunori
AU  - Imada K
AD  - Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
FAU - Yamamura, Ryosuke
AU  - Yamamura R
AD  - Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
FAU - Kosugi, Satoru
AU  - Kosugi S
AD  - Department of Internal Medicine (Hematology), Toyonaka Municipal Hospital, 
      Toyonaka, Japan.
FAU - Shimura, Yuji
AU  - Shimura Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
FAU - Ito, Tomoki
AU  - Ito T
AD  - First Department of Internal Medicine, Kansai Medical University, Moriguchi, 
      Japan.
FAU - Fuchida, Shin-Ichi
AU  - Fuchida SI
AD  - Department of Hematology, Japan Community Health care Organization Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Uchiyama, Hitoji
AU  - Uchiyama H
AD  - Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, 
      Japan.
FAU - Fukushima, Kentaro
AU  - Fukushima K
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Osaka 
      University, Osaka, Japan.
FAU - Yoshihara, Satoshi
AU  - Yoshihara S
AD  - Division of Hematology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya, Japan.
FAU - Hanamoto, Hitoshi
AU  - Hanamoto H
AD  - Department of Hematology, Kindai University Nara Hospital, Ikoma, Japan.
FAU - Tanaka, Hirokazu
AU  - Tanaka H
AD  - Department of Hematology and Rheumatology, Faculty of Medicine, Kindai 
      University, Osakasayama, Japan.
FAU - Uoshima, Nobuhiko
AU  - Uoshima N
AD  - Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
FAU - Ohta, Kensuke
AU  - Ohta K
AD  - Hematology Ohta Clinic, Osaka, Japan.
FAU - Yagi, Hideo
AU  - Yagi H
AD  - Department of Hematology and Oncology, Nara Prefecture General Medical Center, 
      Nara, Japan.
FAU - Shibayama, Hirohiko
AU  - Shibayama H
AD  - Department of Hematology, National Hospital Organization Osaka National Hospital, 
      Osaka, Japan.
FAU - Onda, Yoshiyuki
AU  - Onda Y
AUID- ORCID: 0000-0003-3093-4974
AD  - Department of Hematology, Japanese Red Cross Takatsuki Hospital, Takatsuki, 
      Japan.
FAU - Tanaka, Yasuhiro
AU  - Tanaka Y
AD  - Department of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, 
      Japan.
FAU - Adachi, Yoko
AU  - Adachi Y
AD  - Department of Internal Medicine, Japan Community Health care Organization Kobe 
      Central Hospital, Kobe, Japan.
FAU - Matsuda, Mitsuhiro
AU  - Matsuda M
AD  - Department of Hematology, PL General Hospital, Osaka, Japan.
FAU - Iida, Masato
AU  - Iida M
AD  - Department of Internal Medicine, Kawasaki Hospital, Kaizuka, Japan.
FAU - Miyoshi, Takashi
AU  - Miyoshi T
AD  - Department of Hematology, Uji Tokushukai Hospital, Uji, Japan.
FAU - Matsui, Toshimitsu
AU  - Matsui T
AD  - Department of Hematology, Nishiwaki Municipal Hospital, Nishiwaki, Japan.
FAU - Takahashi, Ryoichi
AU  - Takahashi R
AD  - Department of Hematology, Omihachiman Community Medical Center, Omihachiman, 
      Japan.
FAU - Takakuwa, Teruhito
AU  - Takakuwa T
AD  - Department of Hematology, Graduate School of Medicine, Osaka City University, 
      Suita, Japan.
FAU - Hino, Masayuki
AU  - Hino M
AD  - Department of Hematology, Graduate School of Medicine, Osaka City University, 
      Suita, Japan.
FAU - Hosen, Naoki
AU  - Hosen N
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Osaka 
      University, Osaka, Japan.
FAU - Nomura, Shosaku
AU  - Nomura S
AD  - First Department of Internal Medicine, Kansai Medical University, Moriguchi, 
      Japan.
FAU - Shimazaki, Chihiro
AU  - Shimazaki C
AD  - Department of Hematology, Japan Community Health care Organization Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Matsumura, Itaru
AU  - Matsumura I
AD  - Department of Hematology and Rheumatology, Faculty of Medicine, Kindai 
      University, Osakasayama, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Kuroda, Junya
AU  - Kuroda J
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
CN  - Kansai Myeloma Forum
LA  - eng
PT  - Journal Article
DEP - 20221213
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC9751172
OTO - NOTNLM
OT  - daratumumab
OT  - monocyte
OT  - multiple myeloma
OT  - predictive markers
OT  - beta2 microglobulin
COIS- The authors declare no conflicts of interest except JK received honorarium from 
      Bristol-Myers Squibb Co, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., 
      Ltd., Sanofi K.K. and Ono Pharma Inc., and is an advisory role in Janssen 
      Pharmaceutical K.K, and Novartis Pharma K.K. TI received honorarium from 
      Bristol-Myers Squibb Co, Takeda Pharmaceutical Co., Ltd. and Sanofi K.K.; and 
      research funding from Bristol-Myers Squibb Co. KI received honorarium from 
      Bristol-Myers Squibb Co, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., 
      Ltd., Ono Pharma Inc., Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Celgene K.K., 
      Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical 
      Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd. and Meiji 
      Seika Pharma Co. Ltd. SF received honoraria from Takeda Pharmaceutical Co., Ltd., 
      Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., 
      Bristol-Myers Squibb Co., Ltd., and Celgene K.K. HT received personal fees from 
      Bristol-Myers Squibb Co (Celgene K.K.), personal fees from Novartis Pharma K.K., 
      grants from Kyowa Kirin Co., Ltd. HS reports honoraria from Takeda Pharmaceutical 
      Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Celgene K.K., 
      Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., 
      AstraZeneca K.K., AbbVie G.K., SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., and 
      Kyowa Kirin Co., Ltd.; and research funding from Pharma Essentia Japan K.K., 
      Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Celgene K.K., Novartis 
      Pharma K.K., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., Eisai Co., Ltd., HUYA 
      Bioscience International, LLC., and Chugai Pharmaceutical Co., Ltd.; and 
      scholarship endowment from Astellas Pharma Inc., Teijin Pharma Ltd., Shionogi & 
      Co., Ltd., Eisai Co., Ltd., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and 
      Nippon Shinyaku Co., Ltd. CS received honoraria from Bristol-Myers Squibb Co., 
      Celgene K.K., Janssen Pharmaceutical K.K., and Sanofi K.K. IM received personal 
      fees from Bristol-Myers Squibb Co. (Celgene K.K.), personal fees from Novartis 
      Pharma K.K., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., 
      personal fees from Pfizer Japan Inc., during the conduct of the study; grants 
      from Ono Pharmaceutical Co., Ltd., personal fees from Janssen Pharmaceutical K.K, 
      grants from Nippon Shinyaku Co., Ltd., grants from Kyowa Kirin Co., Ltd., grants 
      from Sumitomo Dainippon Pharma Co., Ltd., grants from Shionogi & Co., Ltd., 
      grants from Teijin Pharma Ltd., grants from Boehringer Ingelheim Co., Ltd., 
      grants from Sanofi K.K., grants from Chugai Pharmaceutical Co., Ltd., grants from 
      Eisai Co., Ltd., grants from MSD K.K, grants from Asahi Kasei Pharma Corporation, 
      grants and personal fees from Astellas Pharma Inc., grants and personal fees from 
      Takeda Pharmaceutical Co., Ltd., grants from Japan Blood Products Organization, 
      grants from Nihon Pharmaceutical Co., Ltd., grants and personal fees from AbbVie 
      GK, grants from Taiho Pharmaceutical Co., Ltd., grants from Mitsubishi Tanabe 
      Pharma Corporation, grants from Nippon Kayaku Co., Ltd., grants from CSL Behring 
      LLC, grants from Mundipharma K.K, grants from Ayumi Pharmaceutical Corporation, 
      grants from Eli Lilly Japan K.K., grants from Actelion Pharmaceuticals Japan 
      Ltd., personal fees from Amgen BioPharma K.K., outside the submitted work. AT-K 
      serves as an advisor for Megakaryon and receives research fundings from Ono 
      Pharmaceutical Co., Ltd., DSK, and Cognano. JK received research funding from 
      Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., 
      Ltd., Sanofi K.K., Eisai Co., Ltd., Bristol-Myers Squibb Co., Sysmex, Dainippon 
      Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., AbbVie GK, Teijin Pharma 
      Ltd. and Otsuka Pharmaceutical Co. Ltd., has received honoraria from Janssen 
      Pharmaceutical K.K, Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono 
      Pharmaceutical Co., Ltd., Sanofi K.K., Eisai Co., Ltd., SymBio Pharmaceutical 
      Limited, Bristol-Myers Squibb Co., Astellas Pharma Inc., Pfizer Japan Inc., 
      Nippon Shinyaku Co., Ltd., Daiichi Sankyo Co. Ltd., Dainippon Sumitomo Pharma 
      Co., Ltd., AbbVie G.K. and Otsuka Pharmaceutical Co. Ltd., and is a consultant 
      for Janssen Pharmaceutical K.K, and Bristol-Myers Squibb Co.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/12/13
CRDT- 2022/12/19 03:36
PHST- 2022/07/29 00:00 [received]
PHST- 2022/11/14 00:00 [accepted]
PHST- 2022/12/19 03:36 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/12/13 00:00 [pmc-release]
AID - 10.1177_20406207221142487 [pii]
AID - 10.1177/20406207221142487 [doi]
PST - epublish
SO  - Ther Adv Hematol. 2022 Dec 13;13:20406207221142487. doi: 
      10.1177/20406207221142487. eCollection 2022.